RubrYc Therapeutics logo

RubrYc Therapeutics

RubrYc Therapeutics is focused on improving drug discovery through proprietary insights into critical interactions at the drug/target interface. Using diverse chemical libraries developed and supplied by HealthTell, Inc., RubrYc is training algorithms that inform improved decision-making throughout drug discovery.

RubrYc Therapeutics, is spin-off from HealthTell, Inc. and exclusive rights to HealthTell technology and combines binding information from diverse chemical library assays, with gold-standard drug discovery methods to develop biotherapeutic candidate.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.rubryc.com
Founded2017
Disease Focus
Development Stage
STOCK CODENon Listed
Address
2420 Camino Ramon Suite 125, 94582
San Ramon
United States
Email
Contact Number
+1 650-215-0574

RubrYc Therapeutics is focused on improving drug discovery through proprietary insights into critical interactions at the drug/target interface. Using diverse chemical libraries developed and supplied by HealthTell, Inc., RubrYc is training algorithms that inform improved decision-making throughout drug discovery.

RubrYc Therapeutics, is spin-off from HealthTell, Inc. and exclusive rights to HealthTell technology and combines binding information from diverse chemical library assays, with gold-standard drug discovery methods to develop biotherapeutic candidate.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/linkedin-com-company-rubryc-therapeutics” connections=”true” suffix=””]

RubrYc map the surfaces of drug targets with unprecedented resolution, and to identify off target binding events that hamper drug discovery and development. It combines, protein binding interfaces with diverse molecular libraries, and machine learning technology; giving clearity on interaction in drug activivty.

In Apr 2018, RubrYc Therapeutics recieved 10Mn in Series A in equity financing round, led by Third Point Ventures, with participation by Paladin Capital Group and Vital Venture Capital.